A prospective, open-label, non-randomised clinical trial to evaluate the safety and efficacy of Imupsora in the treatment of Psoriasis
Abstract
Objectives: To evaluate the clinical efficacy and safety of Imupsora Tablet and Ointment in Psoriasis. Material and Methods: A prospective, interventional clinical study was conducted on 50 patients of both sexes, aged between 18-55 years, confirmed with Psoriasis from clinical examination and who were willing to give informed consent. All patients received Imupsora Tablet at a dose of 2 tablets twice a day for 12 weeks and Imupsora Ointment to be applied over the affected areas thrice daily as a thin film and rubbed gently. All patients were evaluated at baseline, 4 weeks, 8 weeks and 12 weeks for parameters of Psoriasis Area Severity Index (PASI); Physician's and Patient's global assessment at end of the study. Observation: Imupsora Tablet and Ointment therapy reduced erythema, scaling, indurations and pruritus by 78.01%, 69.74%, 58.45%, and 56.80% respectively at the end of 12 weeks from baseline. The global assessment of response by physicians showed that 28% of patients showed a good improvement while another 60% showed fair improvement in their condition by the end of 12 weeks of treatment. Similarly, 46% and 42% of the patient's global assessment indicated fair and good response at the end of treatment respectively. Result: Imupsora Tablet and Ointment produced a significant reduction in all the inflammatory/metabolic parameters associated with Psoriasis assessed after 12 weeks of treatment. In addition, a significant improvement in Clinical Global Impression in efficacy and tolerability was also observed. No adverse events were reported by any patients. This indicates that Imupsora Tablet and Ointment is clinically effective and safe for Psoriasis.
Downloads
References
World Health Organization. Global report on psoriasis. World Health Organization, 2016
Hay SI, Abajobir AA, Abate KH et al. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territo¬ries, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390:1260–344.
Dogra S, Mahajan R. Psoriasis: Epidemiology, clinical features, co-morbidities, and clinical scoring. Indian Dermatol Online J. 2016 Nov-Dec;7(6):471-480. doi: 10.4103/2229-5178.193906. PMID: 27990381; PMCID: PMC5134160.
Yamanaka K, Yamamoto O, Honda T. Pathophysiology of psoriasis: A review. J Dermatol. 2021;00:1–10. https://doi.org/10.1111/1346-8138.15913
Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020 May 19;323(19):1945-1960. doi: 10.1001/jama.2020.4006. PMID: 32427307.
Nowak-Perlak M, Szpadel K, Jabłońska I, Pizon M, Woźniak M. Promising Strategies in Plant-Derived Treatments of Psoriasis-Update of In Vitro, In Vivo, and Clinical Trials Studies. Molecules. 2022 Jan 18;27(3):591. doi: 10.3390/molecules27030591. PMID: 35163855; PMCID: PMC8839811.
Benhadou, F.; Mintoff, D.; Schnebert, B.; Thio, H. Psoriasis and Microbiota: A Systematic Review. Diseases 2018, 6, 47.
Carvalho, A.V.E.D.; Romiti, R.; Souza, C.D.S.; Paschoal, R.S.; Milman, L.D.M.; Meneghello, L.P. Psoriasis comorbidities: Complications and benefits of immunobiological treatment. An. Bras. Dermatol. 2016, 91, 781–789.
Bowcock, A.M.; Krueger, J.G. Getting under the Skin: The Immunogenetics of Psoriasis. Nat. Rev. Immunol. 2005, 5, 699–711.
Aghmiuni, A.I.; Khiavi, A.A. Medicinal plants to calm and treat psoriasis disease. Aromat. Med. Plants–Back Nat. 2016, 1, 1–28.
Kaur, A.; Kumar, S. Plants and plant products with potential antipsoriatic activity—A review. Pharm. Biol. 2012, 50, 1573–1591.
Lin, Z.X., Jiao, B.W., Che, C.T., Zuo, Z., Mok, C.F., Zhao, M., Ho, W.K.K., Tse, W.P., Lam, K.Y., Fan, R.Q., Yang, Z.J. and Cheng, C.H.K. (2010), Ethyl acetate fraction of the root of rubia cordifolia L. inhibits keratinocyte proliferation in vitro and promotes keratinocyte differentiation in vivo: potential application for psoriasis treatment. Phytother. Res., 24: 1056-1064. https://doi.org/10.1002/ptr.3079
Guruprasad C. Nille, Anand Kumar Chaudhary, Potential implications of Ayurveda in Psoriasis: A clinical case study, Journal of Ayurveda and Integrative Medicine, Volume 12, Issue 1, 2021, Pages 172-177, ISSN 0975-9476, https://doi.org/10.1016/j.jaim.2020.11.009.
Mishra, Swarnima; Prajapati, Abhay K.; huddar, Vitthal G.. Chronic palmoplantar psoriasis management through Ayurveda: a case study. Journal of Indian System of Medicine 8(1):p 51-56, Jan–Mar 2020. | DOI: 10.4103/JISM.JISM_12_20
Sandhiya,V. U. U., 20193193868, English, Journal article, India, 0976-7908 0976-9242, 8, (3), Surat, Pharma Science Monitor, (93–107), Pharma Science Monitor, Role of secondary metabolite from the root of Hemidesmus indicus against psoriasis (via) semisolid dosage form., (2017)
Baby, A.R.; Freire, T.B.; Marques, G.d.A.; Rijo, P.; Lima, F.V.; Carvalho, J.C.M.d.; Rojas, J.; Magalhães, W.V.; Velasco, M.V.R.; Morocho-Jácome, A.L. Azadirachta indica (Neem) as a Potential Natural Active for Dermocosmetic and Topical Products: A Narrative Review. Cosmetics 2022, 9, 58. https://doi.org/10.3390/cosmetics9030058
Zeng L, Yang T, Yang K, Yu G, Li J, Xiang W and Chen H (2022) Curcumin and Curcuma longa Extract in the Treatment of 10 Types of Autoimmune Diseases: A Systematic Review and Meta-Analysis of 31 Randomized Controlled Trials. Front. Immunol. 13:896476. doi: 10.3389/fimmu.2022.896476
![](https://jaims.in/public/journals/1/article_3382_cover_en_US.jpg)
Copyright (c) 2024 Milind Patil, Nikhil Chaudhari, Rajan Chaudhari
![Creative Commons License](http://i.creativecommons.org/l/by-nc-sa/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Journal of Ayurveda and Integrated Medical Sciences (JAIMS) retains the copyright of the contents of this journal but grant the readers the right to use the contents with terms and conditions under a creative common attribution licenses 4 of Attribution, Share Alike and Non-commercial type (CC BY-NC-SA) that allows copy, distribute, display, and perform the work and make derivative works based on it only for non-commercial purposes.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.